2018/07/28 All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study
![The Asian Pacific Association for the Study of the Liver [APASL]](https://www.apasl.info/wp-apasl/wp-content/themes/apasl/images/header/img_apasl_logo.png){kind=logo}